Pharmaceutical manufacturer for Isotretinoin

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad, deep-scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred Contract Development and Manufacturing Organization (CDMO) partner for personalized medicines, blockbuster drugs and consumer health brand extensions. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 80 billion doses of nearly 8,000 products annually. Its rapidly growing expert workforce exceeds 18,000, including more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, Catalent, Inc. (NYSE:CTLT), is in S&P 500® company, and generated nearly $5 billion in revenue in its 2022 fiscal year.

OLON Group is a prominent worldwide firm specializing in the creation and manufacture of active pharmaceutical ingredients for CDMO and Generics. It serves as a dependable and preferred partner for the pharmaceutical, biotech, and specialty ingredients sectors. With a 2021 turnover of 580 million dollars, OLON provides 300 APIs for the Generic market. The company benefits from a workforce of 2,300 employees, including a highly skilled R&D team of over 300 individuals. This enables OLON to offer comprehensive integrated packages and services to facilitate the full development of APIs, leveraging extensive expertise in both Chemical and Biological processes, all within a full cGMP and regulatory framework. OLON holds approximately 160 active US DMFs and 79 granted CoS. OLON's headquarters is located in Rodano, near Milan, Italy, and it operates 11 manufacturing facilities - 8 in Italy, 1 in Spain, 1 in the USA, and 1 in India. These facilities are designed in accordance with the most stringent international standards. Additionally, OLON has 3 branch offices in Hamburg (Germany), Florham Park, NJ (USA), and Shanghai (China).

Siegfried serves as your favored associate for comprehensive integrated pharmaceutical ingredient and drug product services with manufacturing capabilities globally. Our expertise is crucial for your venture throughout the entire lifespan. Our enthusiasm lies in creating and producing formulations. It is extraordinary for a provider of development and manufacturing services to possess such a blend of inherent technical expertise and knowledge. Pharmaceutical ingredient services entail Tailored Development and Outsourced Manufacturing for both active pharmaceutical ingredients (API) and intermediates, along with our own range of API (opiates and other regulated substances) and documentation featuring independent patented technologies. Clients utilizing our drug product services benefit from a wealth of inherited expertise in intricate oral drug delivery systems, including sterile filling, backed by in-house development, customer development and manufacturing, and a wide array of completed dosage form products. Enhancing chemical processes and formulations is our area of specialization. We collaborate closely with clients to innovate and enhance chemical processes, thus providing additional benefits and value. Siegfried operates at 11 locations globally, spanning both the Eastern and Western Hemispheres, with multi-purpose cGMP chemical manufacturing facilities in Zofingen, Switzerland; Pennsville, New Jersey, USA; Nantong, China; Minden, Germany; Saint-Vulbas, France; Evionnaz, Switzerland; and sites for manufacturing drug products in Zofingen, Switzerland; Malta; Hameln, Germany, Irvine, USA; Barberà del Vallès, Spain and El Masnou, Spain. Count on Siegfried as your preferred partner for more opportunities.

Biophore, founded in 2007, has established itself as a dependable partner in the development and production of unique and intricate pharmaceutical products. With 4 USFDA and EU-certified API manufacturing facilities, a specialized intermediate facility, and a research and development laboratory accommodating 400 scientists, Biophore has positioned itself as a worldwide leader among API companies. It consistently ranks among the top 10 US DMF submitters and has acquired over 150 patents globally in process and polymorph areas. Biophore's facilities have an impressive history of successful inspections by regulatory authorities such as USFDA, EMEA, ANVISA, COFEPRIS, and WHO GMP.

We help our partners solve society’s greatest challenges with technologies like molecular recycling, which takes plastic that would otherwise end up in landfills or incinerators and breaks it down to its original building blocks so it can be used over and over again. Our success has always been built around customer collaboration, and we’ll continue to work together to develop sustainable materials that open up countless possibilities for the future.

Kukjeon Pharmaceutical has been actively contributing to the advancement of South Korea's pharmaceutical industry by supplying active pharmaceutical ingredients (API) developed through 50 years of professional capacity building. Currently, we provide API to more than 200 pharmaceutical and electronics companies domestically and internationally. We are a comprehensive chemical solution provider offering a wide range of chemical-based products and services, supported by an organizational system and the capability to engage in research and development as well as foundational businesses.

Kimia Biosciences, established in 1993, specializes in the production of bulk drugs for various medical segments. With a strong focus on quality and advanced technologies, Kimia aims to achieve global recognition in the production of both APIs and FDFs, while maintaining ethical business practices. The state-of-the-art facilities at Village Bhondsi, Gurugram enable the production of a wide range of APIs. Additionally, Kimia plans to develop its own facilities for lifestyle segments, adhering to international regulatory standards, with the goal of delivering top-quality pharmaceutical products and support to both consumers and healthcare professionals.

The company was established in 1986 and operates as a professional producer of bulk pharmaceutical material and medical intermediates. Changzhou Kony Pharmaceutical Co., Ltd, formerly known as another name in 2008 and later as Shangyao Kony (Changzhou) Pharmaceutical Co., Ltd in 2015, is recognized as a Shanghai Medical Member Enterprise since 2012. Their primary offerings include nucleoside antiviral bulk pharmaceutical material and intermediate, as well as Sartans bulk pharmaceutical and intermediates, known for their substantial output and superior quality.

The Saraf group of enterprises was established by the forward-thinking Shri Mahavir G. Saraf in 1952. Sarex Overseas represents a segment of the Saraf group of corporations, and its primary operations center on being a prominent producer of Fine Chemicals and API Intermediates within India. The corporate headquarters of Sarex Overseas is situated in Mumbai, while its manufacturing facility is located in MIDC, Tarapur, which is approximately 100 kilometers from Mumbai in India. Sarex, which was founded in 2002, has garnered a reputation as a reputable Exporter, Manufacturer, and Supplier in India, focusing on producing Active Pharmaceutical Ingredients (API), Bulk Drug Intermediates, and Veterinary Medicines, including IVERMECTIN EP, among others. The organization's adept team of professionals, under expert guidance, processes all products, and the finished range undergoes thorough scrutiny by quality analysts based on various parameters such as composition, pH value, viscosity, and packaging. The company utilizes top-notch materials for packaging. Sarex specializes in the production of high-quality organic fine chemicals for the pharmaceutical and electronics industries, with a focus on Fridel craft, halogenation, nitration, oxidation, and high-pressure reactions. Notably, Sarex excels in process development and customer synthesis, operates pilot plants, and engages in bulk production of heterocycles like Tetrazoles, Triazines, and Quinazolines, among others. Its multipurpose plants include Glass-lined reactors, Stainless steel reactors, high-pressure reactors, and high vacuum distillation units, all supported by QA, QC, and R&D. The company serves as a supplier to numerous catalogue companies for small and bulk quantities and also provides toll manufacturing for large multinational companies.

HAS Healthcare Advanced Synthesis, previously known as Helsinn Advanced Synthesis SA, specializes in the development and production of Active Pharmaceutical Ingredients (APIs), cGMP Advanced Intermediates, High Potency APIs (HPAPIs), and anticancer compounds for external clients from the clinical phase to commercial supply, on an exclusive basis. The manufacturing facility, established in 1984, is situated in Biasca, Switzerland. The Biasca site undergoes regular inspections by the FDA, SwissMedic, and other global regulatory authorities. Production capacities span from small-scale to large-scale, ranging from grams to tens of kilograms. HAS Healthcare Advanced Synthesis is dedicated to delivering a dependable, top-notch, and customized service as a comprehensive CDMO provider.

GAP is a Greek pharmaceutical company that has been in operation since 1949 and is vertically integrated under EUGMP HACCP standards. The company operates in various business units, including softgel capsules contract manufacturing for Rx, OTC, hormonal, and food supplements; development and manufacture of innovative generic formulations; and the development, manufacture, and promotion of nutraceuticals under the EVIOL brand or private label.